|
Affiliation |
Graduate School of Medicine Doctorial Course in Medicine Organ Function-Oriented Medicine Department of Cardiovascular Medicine |
SATO Teruki
|
|
|
Graduating School 【 display / non-display 】
-
-2006.03
Akita University Faculty of Medicine Graduated
Graduate School 【 display / non-display 】
-
-2014.03
Akita University Graduate School, Division of Medicine Doctor's Course Completed
Campus Career 【 display / non-display 】
-
2021.10-Now
Akita University Graduate School of Medicine Doctorial Course in Medicine Organ Function-Oriented Medicine Department of Cardiovascular Medicine Assistant Professor
-
2015.04-2020.02
Akita University Graduate School of Medicine Doctorial Course in Medicine Public Health and Environmental Medicine Specially-appointed Assistant Professor
Thesis for a degree 【 display / non-display 】
-
Apelin is a positive regulator of ACE2 in failing hearts
Teruki Sato, Takashi Suzuki, Hiroyuki Watanabe, Ayumi Kadowaki, Akiyoshi Fukamizu, Peter P Liu, Akinori Kimura, Hiroshi Ito, Josef M Penninger, Yumiko Imai, Keiji Kuba
The Journal of Clinical Investigation 123 ( 12 ) 5203 - 5211 2014.03 [Refereed]
Single author
Research Achievements 【 display / non-display 】
-
Sato Teruki, Kuba Keiji
Folia Pharmacologica Japonica ( The Japanese Pharmacological Society ) 153 ( 4 ) 172 - 178 2019
<p>Apelin is an endogenous peptide ligand for APJ receptor, which is widely expressed in human body, and exerts various physiological effects such as vasodilation, inotropic effect, water balance, heart development, angiogenesis and energy metabolism. The beneficial effects of Apelin in cardiovascular diseases have been elucidated, and the roles of Apelin in aging-associated diseases are recently implicated. The mechanisms for therapeutic effects of Aplein include an antagonistic action to renin-angiotensin system (RAS) in addition to inotropic and vasodilatory actions. We have revealed that endogenous Apelin negatively regulates RAS via upregulation of Angiotensin converting enzyme 2 (ACE2). In addition, a second ligand for APJ receptor, Elabela/Toddler, was identified as an essential hormone for heart development, and it has been reported to have physiological effects similar to Apelin. We and others have shown that Elabela exerts inotropic and protective effects in the heart. Although the number of heart failure patients is rapidly increasing, the pathophysiology of heart failure remains elusive and further development of new therapeutic option is awaited. Apelin is a unique bifunctional molecule, which has both inotropic and cardioprotective effects in heart failure, and thus further elucidation of the mechanisms for Apelin/Elabela-APJ signaling would contribute to development of a novel therapeutics for heart failure patients.</p>